KMDA
- Kamada Ltd.
()
Overview
Company Summary
Kamada Ltd. (KMDA) is a biopharmaceutical company primarily focused on the development, production, and marketing of specialty plasma-derived protein therapeutics. The company specializes in developing advanced therapeutics derived from human plasma, which are used to treat a variety of medical conditions.
Kamada specializes in the production of Alpha-1 Antitrypsin (AAT) inhaled therapy, a treatment for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder that can lead to lung and liver diseases. AATD affects the liver's ability to produce a specific protein, leading to lung damage caused by chronic obstructive pulmonary disease (COPD). Kamada's AAT therapy helps to replenish the missing protein to improve respiratory function and potentially slow down the progression of lung disease.
Beyond AAT therapy, Kamada also produces other specialty plasma-derived protein therapeutics, including immunoglobulins for various indications and hyperimmune immunoglobulin products. These products are used in the treatment of immune disorders, such as primary immunodeficiency diseases, and as a preventive measure against the transmission of certain diseases.
In addition to their product portfolio, Kamada has established a global distribution network to ensure the availability of their therapeutics to patients in different regions. They partner with various biopharmaceutical companies and distributors to reach patients worldwide.
Overall, Kamada Ltd. focuses on advancing the field of plasma-derived protein therapeutics and making a positive impact on patients' lives by providing treatments for rare and orphan diseases.